TScan Therapeutics (TCRX) Accumulated Expenses (2020 - 2026)

TScan Therapeutics (TCRX) has reported Accumulated Expenses for 7 consecutive years, with $8.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 324.51% year-over-year to $8.6 million; the TTM figure through Mar 2026 stood at $8.6 million (up 324.51% YoY), while the FY2025 annual figure was $4.1 million, down 73.1% from the prior year.
• Accumulated Expenses advanced to $8.6 million in Q1 2026 per TCRX's latest filing, from $4.1 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $15.4 million in Q4 2024 and bottomed at $1.0 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $6.9 million across 5 years, with a median of $5.5 million in 2023.
• Annual changes were most pronounced in 2023 — Accumulated Expenses soared 643.06% — and 2025, when it tumbled 76.96%.
• TScan Therapeutics' Accumulated Expenses stood at $4.4 million in 2022, then grew by 25.73% to $5.5 million in 2023, then jumped by 181.31% to $15.4 million in 2024, then sank by 73.1% to $4.1 million in 2025, then surged by 107.29% to $8.6 million in 2026.
• Business Quant data shows TCRX's Accumulated Expenses at $8.6 million in Q1 2026, $4.1 million in Q4 2025, and $10.8 million in Q3 2025.